Utah Medical Products 2Q FY26 net income drops 11.9% to USD 2.69 million; revenue falls 14.3% to USD 8.53 million
UTMD•First-half performance and outlook
For 1H 2026, net income decreased 13.1% to USD 5.29 million on a 12.3% revenue slide to USD 17.25 million.
Management now expects a 10%-13% full-year 2026 revenue decline versus 2025, citing slower-than-expected new biopharma OEM customer sales.
2Q FY26 results and revenue decline
Utah Medical Products reported 2Q 2026 net income of USD 2.69 million, down 11.9% year over year; diluted EPS fell 10.1% to USD 0.84.
Revenue dropped 14.3% to USD 8.53 million, reflecting no revenue from PendoTECH or its former China distributor.
Operating income declined 17.1% to USD 2.65 million, pressured by USD 213,000 higher U.S. litigation costs.
